Vascular Inflammation Imaging Using Somatostatin Receptor Positron Emission Tomography
CompletedNCT02021188
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This VISION study aims to investigate the role of inflammation in atherosclerosis using 68Ga- DOTATATE PET, and to validate 68Ga-DOTATATE PET imaging for the detection and quantification of vascular inflammation in the aorta, coronary and carotid arteries. This study will test the hypothesis that in subjects undergoing carotid endarterectomy for symptomatic plaques, there will be a positive correlation between carotid artery 68Ga-DOTATATE PET signal and the underlying degree of carotid inflammation measured by immunohistochemical analysis.
Study details
- Official title
- The Vascular Inflammation Imaging Using Somatostatin Receptor Positron Emission Tomography Study
- Conditions
- Atherosclerosis
- Stroke
- Transient Ischemic Attack
- Chronic Stable Angina
- Acute Coronary Syndrome
- Sponsor
- University of Cambridge
- Start date
- 2014-08
- Primary completion
- 2016-08
- Sex
- All
- Age range
- from 40 Years
- Results posted
- No results posted in this snapshot
- Countries
- United Kingdom
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age ≥40 years of age * Can provide written, fully informed consent * Have had a transient ischemic attack (TIA) or stroke within the preceding four weeks due to carotid artery atherosclerosis; or have ≥30% carotid artery or epicardial coronary artery stenosis Exclusion Criteria: * Renal impairment (eGFR\<30mls/min) * History of contrast nephropathy * Atrial fibrillation * Any condition, in the opinion of the investigator, which prevents the participant from lying flat during scanning * Women of childbearing potential * Inability to provide written informed consent * Haemorrhagic stroke within 3 months of study entry * Total occlusion of a culprit carotid artery * Any medical condition, vital sign or laboratory value that, in the opinion of the investigator, makes the subject ineligible for inclusion
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02021188